UK markets open in 3 hours 1 minute

argenx SE (0QW0.IL)

IOB - IOB Delayed price. Currency in EUR
Add to watchlist
349.65+9.90 (+2.91%)
At close: 06:05PM BST
Full screen
Previous close339.75
Open0.00
Bid332.20 x N/A
Ask0.00 x N/A
Day's range0.00 - 0.00
52-week range
Volume39,210
Avg. volume30,547
Market cap20.57B
Beta (5Y monthly)0.53
PE ratio (TTM)N/A
EPS (TTM)-6.55
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease

    ADHERE data show VYVGART® Hytrulo has potential to be first advancement for CIDP patients in 30 years Real-world data demonstrate gMG patients able to significantly reduce steroid use over first six months of initiating VYVGART® treatment April 16, 2024 – 7:00am CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that data from its Phase 3 ADHERE tri

  • Insider Monkey

    Here’s Why argenx SE (ARGX) Pulled Back 23% in Q4

    TimesSquare Capital Management, an equity investment management company, released its “U.S. Mid Cap Growth Strategy” fourth-quarter investor letter. A copy of the same can be downloaded here. In the fourth quarter, the strategy underperformed the Russell Midcap Growth Index and returned 13.66% (gross) and 13.44% (net) while the index return was -14.55%. In addition, please check […]

  • GlobeNewswire

    argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease

    RHO study supports proof-of-concept in primary Sjogren’s disease Decision informed by favorable safety profile and consistency across efficacy and biomarker measures March 27, 2024, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its plan to continue the development of efgartigimod to Phase 3 in adults with primary Sjogren’s disease (SjD)